Filing Details
- Accession Number:
- 0000921895-23-002232
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2023-09-25 19:43:12
- Reporting Period:
- 2023-09-22
- Accepted Time:
- 2023-09-25 19:43:12
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 1262104 | Mei Pharma Inc. | MEIP | Pharmaceutical Preparations (2834) | 510407811 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1491069 | Ross Bruce Winson | 16000 Dallas Parkway Suite 800 Dallas TX 75248 | No | No | Yes | No | |
| 1491072 | Anson Funds Management Lp | 16000 Dallas Parkway Suite 800 Dallas TX 75248 | No | No | Yes | No | |
| 1491073 | Anson Management Gp Llc | 16000 Dallas Parkway Suite 800 Dallas TX 75248 | No | No | Yes | No | |
| 1581079 | Anson Advisors Inc. | 155 University Avenue Suite 207 Toronto A6 M5H 3B7 | No | No | Yes | No | |
| 1585167 | Moez Kassam | 111 Peter Street Suite 904 Toronto A6 M5V2H1 | No | No | Yes | No | |
| 1962354 | Amin Nathoo | 155 University Avenue Suite 207 Toronto Z4 M5H 3B7 | No | No | Yes | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2023-09-22 | 48,060 | $6.85 | 864,188 | No | 4 | P | Indirect | See footnotes |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | P | Indirect | See footnotes |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Put Option (obligation to buy) | Disposition | 2023-09-22 | 9,000 | $0.15 | 900,000 | $7.00 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 9,000 | 2023-09-22 | 2023-10-20 | No | 4 | S | Indirect |
Footnotes
- The filing of this Form 4 shall not be construed as an admission that Anson Funds Management LP ("Anson"), Anson Management GP LLC, the general partner of Anson ("Anson GP"), Bruce R. Winson, the manager of Anson GP, Anson Advisors Inc. ("Anson Advisors"), Amin Nathoo, a director of Anson Advisors, or Moez Kassam, a director of Anson Advisors, is or was for the purposes of Section 16(a) of the Securities Exchange Act of 1934, as amended, or otherwise the beneficial owner of any of the securities of MEI Pharma, Inc. (the "Issuer") purchased by Anson Investments Master Fund LP, Anson East Master Fund LP and Anson Opportunities Master Fund LP (collectively, the "Funds"), each advised by Anson and Anson Advisors.
- Each of the Reporting Persons is a member of a Section 13(d) group that collectively owns more than 10% of the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
- Anson and Anson Advisors hold indirectly the securities of the Issuer through the Funds, for which Anson and Anson Advisors are the Investment Advisors. Anson GP and Bruce R. Winson report the securities held indirectly by the Funds because, as the general partner of Anson and the manager of Anson GP, respectively, at the time of purchase, they controlled the disposition and voting of the securities. Mr. Nathoo and Mr. Kassam report the securities held indirectly by the Funds because, as the directors of Anson Advisors, at the time of purchase, they controlled the disposition and voting of the securities.
Billionaire Hedge Funds
